Trial Profile

A Phase I dose-escalation study of ValloVax for the treatment of non-small stage lung cancer

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 06 Sep 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Placental-derived cell therapy-(ValloVax) (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Batu Biologics

Most Recent Events

20 Aug 2018 According to a Batu Biologics media release, this trial is expected to initiate in late 2018.
07 Nov 2017 According to a Batu Biologics media release, ValloVax, has received an Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) allowing the company to proceed with phase I clinical trials.
26 Jan 2016 According to a Batu Biologics media release, the company expects FDA clearance in the first quarter of 2016 and trial initiation in the second quarter of 2016.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com